SCHEMBL376859

SCHEMBL376859

COC(=O)c1cc(C)c(F)cc1N

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
CFTR P13569 7/20 0.50
ALDH1A1 P00352 6/20 0.50
GAA P10253 5/20 0.50
HSD17B10 Q99714 3/20 0.50
HPGD P15428 3/20 0.50
MAPT P10636 2/20 0.50
GLA P06280 2/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
ABL1 P00519 1/20 0.49
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
POLB P06746 1/20 0.40
IKBKB O14920 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3616519 0.93 KDM4E (0.56) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL195591 0.87 KDM4E (0.61) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL19175223 0.86 KDM4E (0.47) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL681252 0.85 KDM4E (0.63) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL31024710 0.85 MAPT (0.42) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL3436881 0.85 MAPT (0.42) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL20470613 0.83 PDGFRB (0.42) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL14186809 0.83 MAPT (0.41) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL2897750 0.83 KDM4E (0.61) KDM4ECFTRALDH1A1GAAHSD17B10
SCHEMBL12303359 0.82 KDM4E (0.56) KDM4ECFTRALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748843-A2 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2026-05-27 EP disclosed
EP-4556026-A1 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2025-05-21 EP disclosed
EP-4552654-A1 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2025-05-14 EP disclosed
CN-119948034-A Novel peptide-based nitrile compound and application thereof 上海壹迪生物技术有限公司 2025-05-06 CN disclosed
CN-119564878-A Bioactive substance conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-03-07 CN disclosed
CN-119504997-A Bioactive substance conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-02-25 CN disclosed
CN-119497631-A Antibody drug conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-02-21 CN disclosed
CN-119486763-A Antibody drug conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-02-18 CN disclosed
CN-115279417-B Bioactive substance conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-01-03 CN disclosed
CN-117964637-A Novel peptide-based nitrile compound and application thereof 上海壹迪生物技术有限公司 2024-05-03 CN disclosed
US-20100196319-A1 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-08-05 US disclosed
EP-2197884-A2 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-06-23 EP disclosed
EP-2197842-A1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-06-23 EP disclosed
EP-2195317-A1 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-06-16 EP disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 US disclosed
WO-2009032124-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-03-12 WO disclosed
WO-2009032116-A1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 WO disclosed
WO-2009032123-A2 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 WO disclosed
WO-2009032125-A1 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196319-A1 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L KDM4E 554/4885CFTR 1098/4885ALDH1A1 410/4885
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L KDM4E 405/4885CFTR 1780/4885ALDH1A1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.